Home  /  Resource Library  /  Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Results of a phase II study of Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for front line treatment of chronic lymphocytic leukemia with IGHV mutations.